Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012 for this...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study in 21,271 individuals identifies 9 novel loci associated with circulating CD34<sup>+</sup> hematopoietic stem and progenitor cell levels.

HemaSphere·2026
Same author

A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II Inhibition.

Journal of the American Chemical Society·2026
Same author

<i>Ppm1d</i> Clonal Hematopoiesis Does Not Promote Atherosclerosis in Murine Models.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Clonal hematopoiesis in lung adenocarcinoma pathogenesis.

JCI insight·2026
Same author

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

Blood·2026
Same author

Charged molecular glue discovery enabled by targeted degron display.

Nature chemical biology·2026

Related Experiment Video

Updated: May 29, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Stem cell gene expression programs influence clinical outcome in human leukemia.

Kolja Eppert1, Katsuto Takenaka, Eric R Lechman

  • 1Division of Stem Cell and Developmental Biology, Campbell Family Institute for Cancer Research, Ontario Cancer Institute, University Health Network and Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.

Nature Medicine
|August 30, 2011
PubMed
Summary

Cancer stem cells (CSCs) drive leukemia hierarchies. This study confirms that leukemia stem cells (LSCs) in acute myeloid leukemia (AML) are clinically relevant, impacting patient survival and not just a xenotransplantation artifact.

More Related Videos

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
09:34

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations

Published on: October 25, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
03:40

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells
10:25

Pan-myeloid Differentiation of Human Cord Blood Derived CD34+ Hematopoietic Stem and Progenitor Cells

Published on: August 9, 2019

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
09:34

A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations

Published on: October 25, 2018

Area of Science:

  • Hematology
  • Cancer Biology
  • Stem Cell Research

Background:

  • Cancer stem cells (CSCs) are hypothesized to drive tumor growth and recurrence in various cancers, including leukemia.
  • The clinical relevance of the CSC model in human acute myeloid leukemia (AML) remains uncertain, with questions about whether CSCs are genuine biological entities or artifacts of experimental models.

Purpose of the Study:

  • To investigate the relevance of the cancer stem cell (CSC) model in human acute myeloid leukemia (AML).
  • To identify and characterize leukemia stem cells (LSCs) within primary human AML samples.
  • To determine the prognostic significance of LSCs and their associated gene expression signatures in AML patients.

Main Methods:

  • Sorting of multiple cell populations from 16 primary human AML samples.
  • Utilizing a sensitive xenograft assay to identify populations containing leukemia stem cells (LSCs).
  • Gene expression profiling of validated populations to establish LSC- and hematopoietic stem cell (HSC)-specific signatures.
  • Bioinformatic analysis to identify shared transcriptional programs between LSCs and HSCs.

Main Results:

  • Identification of LSC-specific and HSC-specific gene signatures.
  • Discovery of a core transcriptional program shared by LSCs and HSCs, defining 'stemness'.
  • Both LSC and HSC stemness programs were significant independent predictors of patient survival in AML.
  • These stemness signatures were found to be components of existing prognostic signatures for AML.

Conclusions:

  • Leukemia stem cells (LSCs) are clinically relevant in acute myeloid leukemia (AML) and are not merely artifacts of xenotransplantation.
  • The molecular machinery underlying stemness, shared by LSCs and HSCs, significantly influences clinical outcomes in AML.
  • Stemness determinants are crucial prognostic factors in AML, highlighting their importance in understanding disease progression and patient survival.